Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | HRH1 | P35367 | 9/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739672 | 1.00 | MAPT (0.41) | MAPTTP53HRH1CYP2D6KCNH2 | |
| SCHEMBL742139 | 0.90 | NPC1 (0.39) | MAPTTP53HRH1CYP2D6KCNH2 | |
| SCHEMBL741101 | 0.90 | NPC1 (0.39) | MAPTTP53HRH1CYP2D6KCNH2 | |
| SCHEMBL739379 | 0.90 | HRH1 (0.44) | HRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL739378 | 0.90 | HRH1 (0.44) | HRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL738740 | 0.90 | HRH1 (0.46) | HRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL738739 | 0.90 | HRH1 (0.46) | HRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL740155 | 0.89 | HRH1 (0.45) | HRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL740154 | 0.89 | HRH1 (0.45) | HRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL762719 | 0.88 | HRH1 (0.44) | MAPTHRH1CYP2D6KCNH2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | claimed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |